Evolent Health (EVH) reported $479.53 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 22.8%. EPS of $0.05 for the same period compares to $0.04 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $466.43 million, representing a surprise of +2.81%. The company delivered an EPS surprise of -50%, with the consensus EPS estimate being $0.10.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Average PMPM Fees / Revenue per Case - Performance Suite: $14.77 versus $14.26 estimated by three analysts on average.
- Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.40 versus the three-analyst average estimate of $0.36.
- Average PMPM Fees / Revenue per Case - Administrative Services: $15.77 versus $15.20 estimated by three analysts on average.
- Average Lives on Platform / Cases - Cases: 13 thousand versus the three-analyst average estimate of 14.14 thousand.
- Average Lives on Platform / Cases - Performance Suite: 6.47 million compared to the 6.59 million average estimate based on three analysts.
- Average Lives on Platform / Cases - Specialty Technology and Services Suite: 78.05 million versus the three-analyst average estimate of 78.99 million.
- Average Lives on Platform / Cases - Administrative Services: 1.22 million versus the three-analyst average estimate of 1.23 million.
- Average PMPM Fees / Revenue per Case - Cases: $3,236.00 versus $3,044.38 estimated by three analysts on average.
View all Key Company Metrics for Evolent Health here>>>
Shares of Evolent Health have returned -21.1% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Evolent Health, Inc (EVH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
